cbdMD, Inc. (YCBD) Stock Analysis and Metrics

cbdMD

NYSE: YCBD

$0.54 ▼ -0.04 (-7.17%)

At close: Jul 24, 2026 · 3:26 PM UTC

Financial Ratios

Market Cap4.82 Mn

P/E-1.30

P/S0.25

Div. Yield0.00

Revenue Growth (1y) (Qtr)-1.89

Add ratio to table…

About

cbdMD, Inc. is a consumer wellness company specializing in the development, manufacturing, and marketing of supplement brands centered on natural compounds, primarily hemp-derived cannabinoids. The company focuses on creating products that address key wellness needs, including sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. Its portfolio combines scientific research with high manufacturing standards to produce consistent, safe, and regulatory-compliant products. cbdMD operates in the rapidly evolving hemp and cannabinoid-based supplement industry, positioning itself as a leader in innovation and quality.

The company generates revenue through the sale of a diverse range of products, including broad-spectrum and full-spectrum CBD formulations, hemp-derived Delta-9 THC products (where legally permitted), and functional supplements. Its offerings span oils, gummies, capsules, soft-gels, topicals, pet wellness products, and ready-to-drink beverages. Sales are driven through a multi-channel distribution network, comprising direct-to-consumer e-commerce platforms, online marketplaces, wholesale distribution to national and regional retailers, specialty health and pet channels, and international markets. In fiscal 2025, approximately 77% of revenue came from e-commerce, while wholesale and international distribution contributed the remainder.

The company operates through the following segments:

• cbdMD: This segment represents the flagship brand, offering a comprehensive line of hemp-derived cannabinoid products, including oils, gummies, capsules, soft-gels, topicals, and compliant Delta-9 THC formulations. The brand targets human wellness, emphasizing scientific backing, safety, and efficacy to meet consumer demand for high-quality supplements.

• Paw CBD: This segment focuses on pet wellness, providing hemp-derived cannabinoid products such as tinctures, chews, and topicals for dogs and cats. The brand prioritizes safety and quality, catering to pet owners seeking natural solutions for animal health and mobility.

• ATRX: This segment explores emerging and novel non-cannabinoid functional ingredients, including functional mushrooms and performance-driven nutraceuticals. ATRX supports the company’s expansion into nootropic and synergistic ingredient combinations, targeting cognitive and physical performance.

• Herbal Oasis (Oasis): This segment features a premium hemp-derived THC-infused social seltzer, blending cannabinoids and nootropic mushrooms to create a fast-acting, functional beverage. The brand is distributed through beverage and alcohol distributors, as well as retail chains, and is positioned for growth in the ready-to-drink market.

cbdMD operates in a highly competitive and fragmented dietary supplement market, where it distinguishes itself through a focus on hemp-derived cannabinoids and emerging functional ingredients. The U. S. cannabinoid market includes over 2,000 brands, with no single dominant player, creating opportunities for differentiation. The company competes with both public and private companies across e-commerce, wholesale, and brick-and-mortar retail channels. Key competitive advantages include its commitment to clinical research, peer-reviewed studies, and proprietary formulations that substantiate product efficacy and safety. Additionally, cbdMD’s multi-brand portfolio, regulatory compliance, and hybrid manufacturing model enable it to adapt quickly to market trends and regulatory changes. However, the company faces challenges from synthetic cannabinoids and evolving federal regulations, which could impact its product offerings and revenue streams.

The company serves a broad and diverse customer base, including individual consumers, pet owners, retailers, and distributors. Its direct-to-consumer business is driven by e-commerce platforms such as its own websites, while wholesale partners include national and regional retailers like Sprouts, Total Wine, Winn-Dixie, Piggly Wiggly, and GNC. The Oasis brand is distributed through beverage and alcohol distributors, as well as grocery and convenience store chains. Internationally, cbdMD partners with local wholesalers and distributors to navigate regulatory requirements in markets such as Central and South America, the European Union, and the United Kingdom.

Investment Thesis

▲ Bull case

cbdMD is strategically positioning itself at the forefront of regulatory evolution by leveraging the Bluebird Botanicals acquisition to build a unified GRAS and regulatory science platform that consolidates safety and compliance assets across both broad-spectrum and full-spectrum formulations, which management believes creates one of the most comprehensive regulatory dossiers in the industry, enabling credible engagement with CMS and CMMI innovation initiatives as federal healthcare frameworks evolve, potentially unlocking long-term reimbursement pathways and institutional adoption that the market has yet to fully price in given the company's current valuation relative to its growing clinical and regulatory moat.
The launch of cbdMD's clinical healthcare channel, activated by CMS's BEI program effective April 1, 2026, represents a structural shift in market access, allowing the company to supply hemp-derived cannabinoid products to Medicare patients through physician-supervised care in models like EOM and ACO REACH, a channel where cbdMD claims to possess the only combined OECD-standard preclinical toxicology and human RCT data in the hemp-derived CBD category, creating a high-barrier-to-entry advantage that could drive sustainable, high-margin B2B growth as value-based care organizations prioritize evidence-based, compliant suppliers amid increasing regulatory scrutiny.
The Herbal Oasis THC-infused social seltzer expansion into Louisiana via the partnership with Morales Beverage Group taps into the fast-growing functional beverage segment, with U.S. THC beverage sales projected to exceed $3.5 billion by 2030, and Oasis's proprietary formulation combining hemp-derived THC, CBD, CBG, and adaptogenic mushrooms (lion's mane, reishi, cordyceps) differentiates it in a crowded market by targeting functional benefits like focus and calm, positioning the brand to capture share in the alcohol alternative space as consumer preferences shift toward wellness-forward social drinking, a trend supported by strong early performance in Texas and now accelerated by MBG's statewide distribution infrastructure.
cbdMD's Q2 FY26 results showed 19% year-over-year and 12% sequential revenue growth, with core business growth (excluding Bluebird) reaching its highest level since Q1 FY24, indicating that the company's organic momentum is strengthening independently of acquisition contributions, while the integration of Bluebird Botanicals is unlocking cost synergies through internalized regulatory science and shared services, reducing reliance on expensive external consultants and improving operating leverage as scaled production and distribution networks mature post-acquisition.
The company's balance sheet reflects improving liquidity with cash increasing to $2.6 million as of March 31, 2026 from $2.3 million at September 30, 2025, supported by $2.0 million in preferred stock proceeds, providing financial flexibility to fund clinical channel development, Oasis expansion, and potential tuck-in acquisitions without immediate dilution pressure, while the reduced net loss per share ($0.12 basic/diluted in H1 FY26 vs $3.67 in H1 FY25) signals meaningful progress toward profitability despite ongoing investments in regulatory science and channel expansion, suggesting the market may be underestimating the inflection point in operational efficiency as scale benefits from the Bluebird integration begin to materialize.

cbdMD is strategically positioning itself at the forefront of regulatory evolution by leveraging the Bluebird Botanicals acquisition to build a unified GRAS and regulatory science platform that consolidates safety and compliance assets across both broad-spectrum and full-spectrum formulations, which management believes creates one of the most comprehensive regulatory dossiers in the industry, enabling credible engagement with CMS and CMMI innovation initiatives as federal healthcare frameworks evolve, potentially unlocking long-term reimbursement pathways and institutional adoption that the market has yet to fully price in given the company's current valuation relative to its growing clinical and regulatory moat.
The launch of cbdMD's clinical healthcare channel, activated by CMS's BEI program effective April 1, 2026, represents a structural shift in market access, allowing the company to supply hemp-derived cannabinoid products to Medicare patients through physician-supervised care in models like EOM and ACO REACH, a channel where cbdMD claims to possess the only combined OECD-standard preclinical toxicology and human RCT data in the hemp-derived CBD category, creating a high-barrier-to-entry advantage that could drive sustainable, high-margin B2B growth as value-based care organizations prioritize evidence-based, compliant suppliers amid increasing regulatory scrutiny.
The Herbal Oasis THC-infused social seltzer expansion into Louisiana via the partnership with Morales Beverage Group taps into the fast-growing functional beverage segment, with U.S. THC beverage sales projected to exceed $3.5 billion by 2030, and Oasis's proprietary formulation combining hemp-derived THC, CBD, CBG, and adaptogenic mushrooms (lion's mane, reishi, cordyceps) differentiates it in a crowded market by targeting functional benefits like focus and calm, positioning the brand to capture share in the alcohol alternative space as consumer preferences shift toward wellness-forward social drinking, a trend supported by strong early performance in Texas and now accelerated by MBG's statewide distribution infrastructure.
cbdMD's Q2 FY26 results showed 19% year-over-year and 12% sequential revenue growth, with core business growth (excluding Bluebird) reaching its highest level since Q1 FY24, indicating that the company's organic momentum is strengthening independently of acquisition contributions, while the integration of Bluebird Botanicals is unlocking cost synergies through internalized regulatory science and shared services, reducing reliance on expensive external consultants and improving operating leverage as scaled production and distribution networks mature post-acquisition.
The company's balance sheet reflects improving liquidity with cash increasing to $2.6 million as of March 31, 2026 from $2.3 million at September 30, 2025, supported by $2.0 million in preferred stock proceeds, providing financial flexibility to fund clinical channel development, Oasis expansion, and potential tuck-in acquisitions without immediate dilution pressure, while the reduced net loss per share ($0.12 basic/diluted in H1 FY26 vs $3.67 in H1 FY25) signals meaningful progress toward profitability despite ongoing investments in regulatory science and channel expansion, suggesting the market may be underestimating the inflection point in operational efficiency as scale benefits from the Bluebird integration begin to materialize.

▼ Bear case

cbdMD's continued reliance on external financing, evidenced by the $2.0 million preferred stock issuance in Q2 FY26 to fund operations, highlights persistent cash burn and an inability to generate sustainable internal cash flow, with the company reporting a net loss of $1.1 million for the six months ended March 31, 2026 and an adjusted EBITDA loss of $234,590, suggesting that despite revenue growth, the business remains fundamentally unprofitable and dependent on capital markets to sustain operations, a risk exacerbated by the dilutive impact of preferred stock issuances and the lack of a clear timeline to GAAP profitability amid rising costs from regulatory investments and channel expansion.
The clinical healthcare channel launch, while promising, faces significant adoption barriers as the CMS BEI program remains a limited, model-specific incentive—not a broad reimbursement mechanism—and participating accountable care organizations and oncology practices retain full discretion over supplier selection, meaning cbdMD must invest heavily in clinical relationships and product customization without guaranteed volume commitments, and the company's acknowledgment that physicians require 'institutional-grade documentation' implies ongoing, high-cost efforts to maintain credibility in a channel where market acceptance is uncertain and sales cycles are long, potentially resulting in sunk costs without proportional returns if adoption lags expectations.
The Herbal Oasis expansion into Louisiana, while expanding geographic reach, operates in a highly competitive and fragmented THC beverage market where brand loyalty is low and regulatory uncertainty persists at the state level, with the company's dependence on third-party distributors like MBG limiting pricing power and margin expansion, and the functional claims surrounding adaptogenic mushrooms (lion's mane, reishi, cordyceps) lack robust clinical validation in beverage formats, raising the risk that consumer appeal may be driven more by novelty than sustained demand, particularly as larger CPG players enter the space with greater marketing resources and distribution scale.
Integration risks from the Bluebird Botanicals acquisition remain underappreciated, as the company has not disclosed detailed synergy capture metrics or integration timelines beyond vague references to 'operational efficiencies' and 'shared services,' and the assumption that internal regulatory science can replace costly external consultants overlooks potential knowledge gaps or talent retention challenges post-acquisition, especially given Bluebird's historical emphasis on scientific discipline, which may not align seamlessly with cbdMD's existing culture, risking value erosion rather than creation if cultural or operational misalignment disrupts product development or commercial execution.
cbdMD's exposure to evolving federal and state regulations presents a material overhang, as the company's growth strategy hinges on favorable developments in CMS innovation initiatives and federal rescheduling of cannabis, yet the announcement explicitly cites 'changes in federal and state laws and regulations governing hemp, CBD, and cannabis products, including the potential impact of restrictive hemp legislation' as a risk factor, and with multiple states advancing conflicting regulatory frameworks—some imposing bans on certain cannabinoid products—the company's national rollout strategy for products like full-spectrum extracts or THC beverages could face abrupt legal constraints, undermining the scalability of its regulatory science investments and channel-specific initiatives if federal clarity fails to materialize or if state-level pushback intensifies.

cbdMD's continued reliance on external financing, evidenced by the $2.0 million preferred stock issuance in Q2 FY26 to fund operations, highlights persistent cash burn and an inability to generate sustainable internal cash flow, with the company reporting a net loss of $1.1 million for the six months ended March 31, 2026 and an adjusted EBITDA loss of $234,590, suggesting that despite revenue growth, the business remains fundamentally unprofitable and dependent on capital markets to sustain operations, a risk exacerbated by the dilutive impact of preferred stock issuances and the lack of a clear timeline to GAAP profitability amid rising costs from regulatory investments and channel expansion.
The clinical healthcare channel launch, while promising, faces significant adoption barriers as the CMS BEI program remains a limited, model-specific incentive—not a broad reimbursement mechanism—and participating accountable care organizations and oncology practices retain full discretion over supplier selection, meaning cbdMD must invest heavily in clinical relationships and product customization without guaranteed volume commitments, and the company's acknowledgment that physicians require 'institutional-grade documentation' implies ongoing, high-cost efforts to maintain credibility in a channel where market acceptance is uncertain and sales cycles are long, potentially resulting in sunk costs without proportional returns if adoption lags expectations.
The Herbal Oasis expansion into Louisiana, while expanding geographic reach, operates in a highly competitive and fragmented THC beverage market where brand loyalty is low and regulatory uncertainty persists at the state level, with the company's dependence on third-party distributors like MBG limiting pricing power and margin expansion, and the functional claims surrounding adaptogenic mushrooms (lion's mane, reishi, cordyceps) lack robust clinical validation in beverage formats, raising the risk that consumer appeal may be driven more by novelty than sustained demand, particularly as larger CPG players enter the space with greater marketing resources and distribution scale.
Integration risks from the Bluebird Botanicals acquisition remain underappreciated, as the company has not disclosed detailed synergy capture metrics or integration timelines beyond vague references to 'operational efficiencies' and 'shared services,' and the assumption that internal regulatory science can replace costly external consultants overlooks potential knowledge gaps or talent retention challenges post-acquisition, especially given Bluebird's historical emphasis on scientific discipline, which may not align seamlessly with cbdMD's existing culture, risking value erosion rather than creation if cultural or operational misalignment disrupts product development or commercial execution.
cbdMD's exposure to evolving federal and state regulations presents a material overhang, as the company's growth strategy hinges on favorable developments in CMS innovation initiatives and federal rescheduling of cannabis, yet the announcement explicitly cites 'changes in federal and state laws and regulations governing hemp, CBD, and cannabis products, including the potential impact of restrictive hemp legislation' as a risk factor, and with multiple states advancing conflicting regulatory frameworks—some imposing bans on certain cannabinoid products—the company's national rollout strategy for products like full-spectrum extracts or THC beverages could face abrupt legal constraints, undermining the scalability of its regulatory science investments and channel-specific initiatives if federal clarity fails to materialize or if state-level pushback intensifies.

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	88.07 Bn	103.29	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.75 Bn	23.02	2.06	16.63 Bn
3	ZTS	Zoetis Inc.	31.84 Bn	12.05	3.35	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	27.18 Bn	-10.29	0.59	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.09 Bn	17.93	7.28	-
6	RDHL	RedHill Biopharma Ltd.	21.32 Bn	2,931.66	2.24	-
7	VTRS	Viatris Inc	19.96 Bn	-67.32	1.37	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.66 Bn	26.41	5.69	-

Research Tools

Developers

About

Investment Thesis

Contract with Customer, Sales Channel Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Contract with Customer, Sales Channel Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password